Status:
COMPLETED
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
Lead Sponsor:
Novartis
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
16-65 years
Phase:
PHASE3
Brief Summary
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult ...
Eligibility Criteria
Inclusion
- Patients who had completed the core study and whose participation in this study was considered appropriate as judged by the investigator
- Patients who had given written informed consent to participation in this study
Exclusion
- Patients who failed in treatment compliance in the core study
- Patients who had a major violation of the protocol in the core study
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00232011
Start Date
May 1 2004
End Date
May 1 2005
Last Update
December 17 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
This study is not being conducted in the United States
Various Cities, Japan